Embecta (NASDAQ:EMBC) Releases FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.700-2.900 for the period, compared to the consensus estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Trading Up 10.1 %

EMBC stock opened at $20.59 on Thursday. The stock has a market capitalization of $1.19 billion, a P/E ratio of 17.16 and a beta of 0.97. Embecta has a 12 month low of $9.93 and a 12 month high of $20.80. The firm has a 50-day moving average price of $14.48 and a 200-day moving average price of $14.11.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Friday, December 6th will be issued a $0.15 dividend. The ex-dividend date is Friday, December 6th. This represents a $0.60 dividend on an annualized basis and a yield of 2.91%. Embecta’s dividend payout ratio (DPR) is presently 50.00%.

Analysts Set New Price Targets

Separately, BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Wednesday.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.